Latest Listings And Ipos News

Fonterra Shareholders' Fund has secured conditional approval to delist from the ASX, aiming to consolidate its trading on the NZX by late February 2025. This move is expected to streamline operations and reduce costs for unitholders.

Resources & Energy Group Ltd (REZ) has clarified recent trading activity in its shares, attributing the surge to a significant rise in gold prices rather than undisclosed information. The company remains focused on its Maranoa gold recovery program, with further results pending.

Yancoal Australia announces the resignation of CEO David Moult after five years in the role, with Ning Yue appointed as acting CEO during the search for a permanent successor.

Cardno Limited has requested an immediate suspension from ASX quotation to facilitate its removal from the official ASX list, marking a significant step in its delisting process.

First Graphene Limited has responded to an ASX price query, attributing its recent share price and volume surge to increased buying activity in Germany linked to prior commercial announcements, while reaffirming full compliance with ASX disclosure rules.

Nex Metals Explorations has repriced and partially completed its capital raise, securing $1.06 million at a reduced share price to fund development and exploration activities.

The Supreme Court of New South Wales has approved the scheme of arrangement for Southern Cross Gold Consolidated Ltd to acquire all remaining shares of Southern Cross Gold Ltd, setting the stage for a significant ownership consolidation and ASX trading changes.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.

Latrobe Magnesium Limited has responded to an ASX price query, denying any undisclosed information that could explain the recent sharp drop in its share price and surge in trading volume.

Amcor plc and Berry Global Group, Inc. have entered into a definitive merger agreement for an all-stock transaction valued at approximately $9.9 billion. The combined entity aims to leverage significant synergies and enhanced market reach, pending shareholder and regulatory approvals.

Telix Pharmaceuticals has exceeded its full-year 2024 revenue guidance, driven by strong sales of its prostate cancer diagnostic Illuccix® and strategic pipeline advancements.

The Australian Takeovers Panel has declared unacceptable circumstances in Alara Resources Limited's recent rights issue, citing inadequate disclosure and potential control issues involving Al Tasnim Infrastructure LLC. The company faces a costs order and must reassess its fundraising approach.